On Monday, a joint symposium sponsored by SSAT and the American Society of Colon and Rectal Surgeons (ASCRS) will highlight efforts to improve rectal cancer treatment in the U.S.
The ongoing fight against deadly “superbugs” is aimed at an elusive goal — finding a way to allow antibiotics to do their crucial work, while
GERD is extremely common, with up to one in four American adults experiencing symptoms at least once a month. The mainstay of treatment is proton
Chicago offers DDW® attendees unparalleled sophistication and style, not to mention breathtaking views from Navy Pier and two of the tallest buildings in North America.
Four experts will discuss key considerations when making surgical decisions for cirrhotic patients during Tuesday’s DDW® Clinical Symposium, Cirrhosis and Surgery: Identifying and Managing, which
Chicago may be famous for its deep dish pizza and stacked hot dogs, but gourmet options are right around the corner in one of the
‘Your life’s work should be fun. If it’s nothing more than a job, it’s time to find your passion.
That was the message from SSAT President Nathaniel J. Soper, MD, who recounted his professional journey Sunday morning at DDW® during the annual SSAT Presidential Address.
Caring for patients with IBD requires a multidisciplinary approach. So the organizers of Tuesday’s DDW® Clinical Symposium Endoscopic and Surgical Principles in IBD set out to create a multidisciplinary educational program. The 90-minute symposium is jointly sponsored by AGA, ASGE and SSAT.
Have an idea for a new medical device, technology or service? Getting it to market is a complex, time-consuming process that requires analytical and management skills, great communication, collaboration and leadership, according to Virender Sharma, MD, AGAF, who shared lessons he’s learned as a physician innovator on Saturday at DDW® during a session sponsored by the AGA Center for GI Innovation and Technology.
The management of hepatocellular cancer (HCC) saw meaningful advances in 2016 with the introduction of two compounds, regorafenib and lenvatinib, for patients with advanced HCC.
